Skip to main content

Curran Terrie's Form 4 filing

Phathom Pharmaceuticals, Inc.PHAT · filed Jan 20, 2023

Accession no.
0001209191-23-004341
Filed
Jan 20, 2023
Trade date
Jan 19-20, 2023
Filing delay
1 day
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $47.7K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Curran TerrieCIK 0001690298Director, Officer (President and Chief Executive)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 19, 2023Common StockAGrant or awardAcquired+97,500$0.00$0182,628Direct
Jan 20, 2023Common StockSSaleDisposed−5,821$8.20F3−$47,732.2176,807Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jan 19, 2023Common StockAGrant or awardAcquired+162,500$0.00$0162,500Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F3

Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.16 to $8.20. The reporting person undertakes to provide the Issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)